|
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
RECRUITINGPhase 3Sponsored by University Hospital, Rouen
Actively Recruiting
PhasePhase 3
SponsorUniversity Hospital, Rouen
Started2025-09-25
Est. completion2030-02
Eligibility
Age18 Years – 70 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06123156
Summary
This study aims to evaluate the efficacy of erectile rehabilitation with Sildenafil, in men treated with neoadjuvant proctectomy and radiotherapy for rectal cancer, in preventing long-term erectile dysfunction at 12 months post-operatively.
Eligibility
Age: 18 Years – 70 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria: * Men aged 18 to 70 * Patients undergoing surgery for cancer of the lower or middle rectum by total removal of the mesorectum with colorectal or coloanal anastomosis after neoadjuvant radiotherapy, with normal preoperative erectile function (defined by a combined IIEF erectile function domain score of at least 22). * Nerve-conserving surgery * Sexually active patient without treatment for erectile function prior to surgery * Presence of a regular sexual partner (male or female) * Adult having read and understood the information letter and signed the consent form * Membership of a social security scheme Exclusion Criteria: * T4 tumor or tumor requiring extended surgery * Patients with abnormal erectile function defined by a combined IIEF erectile function domain score of less than 22. * History of prostate cancer * Sleep disorders, patients taking sedatives/hypnotics * Contraindication to SILDENAFIL EG 50 mg, film-coated tablet * Contraindication to placebo * Patients already treated with PDE5 inhibitors * Patients suffering from SARS COV 2\* * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship. * Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol, or to prevent the subject from giving informed consent. * Person participating in another drug trial.
Conditions2
CancerRectal Cancer
Interventions1
Related trials
- PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) — The Netherlands Cancer Institute
- Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis — Topadur Pharma AG
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorUniversity Hospital, Rouen
Started2025-09-25
Est. completion2030-02
Eligibility
Age18 Years – 70 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06123156